SCHEMBL4168652

SCHEMBL4168652

C=C1C[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@]1(OC(C)=O)C(C)=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.70
NR3C1 P04150 4/20 0.70
CYP3A4 P08684 3/20 0.70
PGR P06401 3/20 0.70
AR P10275 2/20 0.70
SHBG P04278 2/20 0.70
ALDH1A1 P00352 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
ABCC4 O15439 1/20 0.70
ABCB11 O95342 1/20 0.70
ESR1 P03372 1/20 0.70
CHRM2 P08172 1/20 0.70
NR3C2 P08235 1/20 0.70
CHRM1 P11229 1/20 0.70
HRH2 P25021 1/20 0.70
AKR1C3 P42330 1/20 0.70
AKR1C2 P52895 1/20 0.70
AKR1C1 Q04828 1/20 0.70
NPSR1 Q6W5P4 1/20 0.70
ESR2 Q92731 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168654 1.00 LMNA (0.70) LMNANR3C1CYP3A4PGRAR
SCHEMBL4168651 1.00 LMNA (0.70) LMNANR3C1CYP3A4PGRAR
SCHEMBL571579 0.83 LMNA (0.65) LMNANR3C1CYP3A4PGRAR
SCHEMBL29356176 0.83 LMNA (0.70) LMNANR3C1CYP3A4PGRAR
SCHEMBL10900154 0.83 LMNA (0.70) LMNANR3C1CYP3A4PGRAR
SCHEMBL10900163 0.83 LMNA (0.70) LMNANR3C1CYP3A4PGRAR
Medroxyprogesterone Acetate SCHEMBL10080145 0.82 NR3C1 (1.00) LMNANR3C1CYP3A4PGRAR
Medroxyprogesterone Acetate SCHEMBL4276 0.82 NR3C1 (1.00) LMNANR3C1CYP3A4PGRAR
Medroxyprogesterone Acetate SCHEMBL22761990 0.82 NR3C1 (1.00) LMNANR3C1CYP3A4PGRAR
Medroxyprogesterone Acetate SCHEMBL3892232 0.82 NR3C1 (1.00) LMNANR3C1CYP3A4PGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580772-B2 Combination therapies using melengestrol acetate and zilpaterol or its salts INTERVET INC. (US) 2013-11-12 US disclosed
US-20090181906-A1 Combination Therapies using Melengestrol Acetate and Zilpaterol or its Salts INTERVET INTERNATIONAL B.V. (NL) 2009-07-16 US disclosed
US-4443377-A Isomerization-acylation process THE UPJOHN COMPANY (US) 1984-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181906-A1 Combination Therapies using Melengestrol Acetate and Zilpaterol or its Salts MC4R, MELK, MC2R LMNA 3026/4885NR3C1 74/4885CYP3A4 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.